The Role of Igm and Complement in Antibody Responses

Total Page:16

File Type:pdf, Size:1020Kb

The Role of Igm and Complement in Antibody Responses Trassla inte till saken genom att komma dragande med fakta Groucho Marx List of Papers This thesis is based on the following papers, which are referred to in the text by their Roman numerals. Ia Rutemark C, Alicot E, Bergman A, Ma M, Getahun A, Ellmerich S, Carroll M, Heyman B. Requirement for complement in antibody responses is not explained by the classic pathway activator IgM. Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):E934-42. Epub 2011 Oct 10. Ib Rutemark C, Alicot E, Bergman A, Ma M, Getahun A, Ellmerich S, Carroll M, Heyman B. Requirement for complement in antibody responses is not explained by the classic pathway activator IgM. Author summary. Proc Natl Acad Sci U S A 2011 108(43): 17589-90 II Carlsson F, Getahun A, Rutemark C, Heyman B. Impaired antibody responses but normal proliferation of specific CD4+ T cells in mice lacking complement receptors 1 and 2. Scand J Immunol. 2009 Aug;70(2):77-84. III Rutemark C, Bergman A, Getahun A, Henningson-Johnson F, Hallgren J, Heyman B. B cells lacking complement receptors 1 and 2 are equally efficient producers of IgG in vivo as wildtype B cells. Manuscript. Reprints were made with permission from the respective publishers. Contents Introduction ................................................................................................... 11 Background ................................................................................................... 12 B cells ....................................................................................................... 12 Antibodies ................................................................................................ 12 T cells ....................................................................................................... 13 Antigen presentation and T cell activation ............................................... 13 Antibody feedback regulation .................................................................. 14 IgG-mediated suppression of antibody responses ............................... 14 Antibody-mediated enhancement of antibody responses .................... 15 IgM-mediated enhancement of antibody responses ............................. 15 The complement system in antibody responses ....................................... 18 Component 3 ........................................................................................ 18 Lectin pathway .................................................................................... 20 Alternative pathway ............................................................................. 20 Classical pathway ................................................................................ 21 Activators of C1q ................................................................................. 23 The C1q paradox in primary antibody responses ................................ 24 Complement Receptors 1 and 2 ........................................................... 25 Possible mechanisms for the importance of complement in antibody responses .............................................................................................. 27 Present investigation ..................................................................................... 29 Aims ......................................................................................................... 29 Paper Ia ................................................................................................ 29 Paper II ................................................................................................ 29 Paper III ............................................................................................... 29 Experimental setup ................................................................................... 30 Mice ..................................................................................................... 30 Immunizations and antigens ................................................................ 31 Adoptive transfer of T cells ................................................................. 31 Assays .................................................................................................. 31 Bone marrow chimeras ........................................................................ 31 Statistical analyses ............................................................................... 32 Results and discussion .............................................................................. 33 Requirement for complement in antibody responses is not explained by the classic pathway activator IgM (Paper Ia) ....................................... 33 Impaired antibody responses but normal proliferation of specific CD4+ T cells in mice lacking complement receptors 1 and 2 (Paper II) ....... 38 B cells lacking complement receptors 1 and 2 are equally efficient producers of IgG in vivo as wildtype B cells (Paper III) ..................... 40 Highlights of this thesis ................................................................................ 44 Acknowledgements ....................................................................................... 45 References ..................................................................................................... 47 Abbreviations APC antigen presenting cells BCIP/NBT 5-bromo-4-chloro-3-indolylphosphate p-toluidine salt and nitro blue tetrazololium HRBC horse red blood cells BCR B cell receptor Bf complement factor B BM bone marrow BSA bovine serum albumin CD cluster of differentiation CGG chicken gamma globulin CR1, 2 complement receptor 1, 2 CVF cobra venom factor CRP c-reactive protein DC dendritic cells DNP 2, 4-dinitrophenol ELISA enzyme-linked immunosorbent assay ELISPOT enzyme-linked immunospot assay Fc fragment crystallizable FDC follicular dendritic cells Fo B follicular B GC germinal center IC immune complex IgG, M… immunoglobulin G, M… IgM-IC antigen-specific IgM in complex with that antigen KLH keyhole limpet hemocyanin mAb monoclonal antibody MASP mannose-associated serine protease MAC membrane attack complex MBL mannose-binding lectin NP 4-hydroxy-3-nitrophenylacetyl MZ marginal zone OVA ovalbumin PBS phosphate buffered saline PFC plaque forming cell assay SAP serum amyloid P component SIGN-R1 specific intracellular adhesion molecule-grabbing noninteg- rin related gene 1 SCR short consensus repeats SRBC sheep red blood cells TCR T cell receptor TH T helper cell TD thymus-dependent TI thymus-independent TNP 2, 4, 6-trinitrophenol WT wildtype Introduction The immune system is our protection against foreign material such as viruses and bacteria, but also in clearing the body from dead cells and cancer cells. Assigned to the immune system are two global functions, recognition and response. In the recognition phase the ability to discriminate between self and non-self-structures, as well as the distinction between different foreign structures is paramount. Following optimal recognition comes then an ap- propriate and specific response. The immune system is often divided into innate immunity and adaptive immunity. The innate cells and molecules are encoded before an infection has occurred. Thus, this part is our very first line of defense, acting fast and with a broad spectrum of recognition. In contrast, the adaptive part is fairly slow to initiate and requires an intact innate defense to mount a full re- sponse. However, once this is fulfilled the adaptive system utilizes the torpe- does of the immune system, the antibodies, produced by B cells, but also cell-mediated defense caused by cytotoxic T cells. The antibodies are highly specific with the ability to discriminate targets that differ down to only one amino acid. However, antibodies recognizing self-antigens are one of the major causes for autoimmunity. Furthermore, the adaptive system also pos- sesses immunological memory, i e the same infection the second time around is responded to faster and with even higher affinity and specificity. Antibodies themselves have the ability to regulate the production of anti- bodies, a process called antibody feedback regulation. The outcome of this regulation can be either enhancement or suppression of the antibody re- sponse, depending on the antibody type or antigen involved. One of the connections between innate and adaptive immunity is the complement system, which is activated via different pathways upon recogni- tion of foreign surfaces. It consists of a group of soluble proteins and recep- tors that can, in very low concentrations, identify and incapacitate many pathogens. The complement system has shown various characteristics in engaging and enhancing the adaptive response, including antibody respons- es. In addition, complement deficiencies often lead to diseases such as auto- immunity. This thesis focuses on the factors that are activating complement and how complement further is affecting the antibody response. More specifically, the classical activation pathway and its most common activator, IgM, have been studied, along with the effect of the complement receptors 1 and 2. 11 Background B cells B lymphocytes (B cells) originate from the bone marrow (BM) and when they are let out into the circulation, each B cell carries a unique antigen- binding receptor on its surface. This receptor is an IgM antibody molecule bound to the B-cell membrane and is referred to as the B cell receptor (BCR). Mature B cells that meet the antigen recognized by the BCR, will start to proliferate and differentiate into antibody producing
Recommended publications
  • Fcγr Binding and ADCC Activity of Human Igg Allotypes
    fimmu-11-00740 May 4, 2020 Time: 17:25 # 1 ORIGINAL RESEARCH published: 06 May 2020 doi: 10.3389/fimmu.2020.00740 FcgR Binding and ADCC Activity of Human IgG Allotypes Steven W. de Taeye1,2*†, Arthur E. H. Bentlage2, Mirjam M. Mebius3, Joyce I. Meesters3, Suzanne Lissenberg-Thunnissen2, David Falck4, Thomas Sénard4, Nima Salehi1, Manfred Wuhrer4, Janine Schuurman3, Aran F. Labrijn3, Theo Rispens1‡ and Gestur Vidarsson2‡ 1 Sanquin Research and Landsteiner Laboratory, Department of Immunopathology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, 2 Sanquin Research and Landsteiner Laboratory, Department of Experimental Edited by: Immunohematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, 3 Genmab, Utrecht, Eric O. Long, Netherlands, 4 Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands National Institute of Allergy and Infectious Diseases (NIAID), United States Antibody dependent cellular cytotoxicity (ADCC) is an Fc-dependent effector function Reviewed by: of IgG important for anti-viral immunity and anti-tumor therapies. NK-cell mediated Amy W. Chung, ADCC is mainly triggered by IgG-subclasses IgG1 and IgG3 through the IgG-Fc- The University of Melbourne, Australia receptor (FcgR) IIIa. Polymorphisms in the immunoglobulin gamma heavy chain gene Geoffrey Thomas Hart, University of Minnesota Twin Cities, likely form a layer of variation in the strength of the ADCC-response, but this has United States never been studied in detail. We produced all 27 known IgG allotypes and assessed *Correspondence: FcgRIIIa binding and ADCC activity. While all IgG1, IgG2, and IgG4 allotypes behaved Steven W. de Taeye [email protected]; similarly within subclass, large allotype-specific variation was found for IgG3.
    [Show full text]
  • Blood Bank I D
    The Osler Institute Blood Bank I D. Joe Chaffin, MD Bonfils Blood Center, Denver, CO The Fun Just Never Ends… A. Blood Bank I • Blood Groups B. Blood Bank II • Blood Donation and Autologous Blood • Pretransfusion Testing C. Blood Bank III • Component Therapy D. Blood Bank IV • Transfusion Complications * Noninfectious (Transfusion Reactions) * Infectious (Transfusion-transmitted Diseases) E. Blood Bank V (not discussed today but available at www.bbguy.org) • Hematopoietic Progenitor Cell Transplantation F. Blood Bank Practical • Management of specific clinical situations • Calculations, Antibody ID and no-pressure sample questions Blood Bank I Blood Groups I. Basic Antigen-Antibody Testing A. Basic Red Cell-Antibody Interactions 1. Agglutination a. Clumping of red cells due to antibody coating b. Main reaction we look for in Blood Banking c. Two stages: 1) Coating of cells (“sensitization”) a) Affected by antibody specificity, electrostatic RBC charge, temperature, amounts of antigen and antibody b) Low Ionic Strength Saline (LISS) decreases repulsive charges between RBCs; tends to enhance cold antibodies and autoantibodies c) Polyethylene glycol (PEG) excludes H2O, tends to enhance warm antibodies and autoantibodies. 2) Formation of bridges a) Lattice structure formed by antibodies and RBCs b) IgG isn’t good at this; one antibody arm must attach to one cell and other arm to the other cell. c) IgM is better because of its pentameric structure. P}Chaffin (12/28/11) Blood Bank I page 1 Pathology Review Course 2. Hemolysis a. Direct lysis of a red cell due to antibody coating b. Uncommon, but equal to agglutination. 1) Requires complement fixation 2) IgM antibodies do this better than IgG.
    [Show full text]
  • Objectives Complement (C') Complement Proteins Functions Of
    Complement Objectives Foundations of Public Health Identify functions of complement Immunology Recognize the similarities and differences of the three complement pathways Complement Identify important complement components & their functions Identify deleterious effects of complement activation and deficiency 1 2 Complement (C’) Complement Proteins Synthesized in the liver and by several Series of approximately 30 heat-labile proteins cells types (splenic macrophages) Normally inactive in the serum Plays an essential role in Inactive complement proteins known as zymogens inflammation and in facilitating Can be sequentially activated in a antibody effectiveness controlled sequence Amplification of the reaction occurs at each step Severe infections or autoimmune Production of biologically active fragments diseases can result from complement for lysis or killing of the target deficiencies (rare in the population) 3 4 Functions of Complement Functions of Complement Essential role in inflammation Assists antibodies in effector functions (Antibody Dependent Cell- mediated Cytotoxicity- ADCC) Assist in clearing immune complexes Opsonization and facilitation of phagocytosis No antigen specificity 5 6 1 Complement 3 Pathways of Activation Complement Activators Classical Triggered when IgM or certain IgG subclasses bind antigens Alternative (Properdin) Triggered by the deposition of complement protein, C3b, onto microbial surfaces No antibodies required for activation Lectin Triggered by the attachment of plasma mannose-binding lectin (MBL) to microbes No antibodies required for Activators start the domino effect… activation 7 8 Early Steps Late Steps The initial steps vary between pathways Dependent on activating substance C3 convertase quickly forms in all paths to cleave C3 Watch this well-done animation on the activation of complement, the Late steps (after C5 convertase) are same in all pathways steps in the complement pathways, Lead to formation of MAC & the functions of complement.
    [Show full text]
  • Understanding the Complement System
    Understanding the Complement System WHAT IS THE IMMUNE SYSTEM? The immune system is a complex network of organs, cells and proteins which work together to protect the body against infection and disease. WHAT IS THE COMPLEMENT SYSTEM? The complement system is a part of the immune system and is essential to the body’s defense against infection. Classical Pathway Lectin Pathway Alternative Pathway Made up of 3 UNIQUE PATHWAYS (Classical, Lectin and Alternative) Each pathway can become activated to trigger a cascade of protein reactions that initiate an immune response Inflammation Marks pathogen/damaged to detect and eliminate: cells for elimination Bacteria Viruses Inflammation Targeted destruction of damaged cells Dead cells When the complement system is working properly, it is a strong and powerful tool that protects the body against harmful invaders. • brain But when the system is thrown out of • nervous system balance, or dysregulated, the proteins can trigger a dangerous, uncontrolled cascade • blood stream of reactions that attack cells and tissues. • kidneys UNLOCKING THE POTENTIAL OF THE COMPLEMENT SYSTEM Alexion’s pioneering legacy in rare diseases is rooted in being the first to translate the complex biology of the complement system into transformative medicines. 3 DECADES 20 YEARS of complement of real-world evidence demonstrating the safety inhibition research and power of targeted complement inhibitors Dysregulation of the complement system is a key driver of many devastating diseases. Alexion has paved the way for a new class of medicines that inhibit the complement system, prevent further damage and reduce disease symptoms. Alexion is committed to continue unlocking the potential of the complement system and accelerating the discovery and development of new life-changing therapies for even more patients.
    [Show full text]
  • Introduction to the Rh Blood Group.Pdf
    Introduction to the Rhesus Blood Group Justin R. Rhees, M.S., MLS(ASCP)CM, SBBCM University of Utah Department of Pathology Medical Laboratory Science Program Objectives 1. Describe the major Rhesus (Rh) blood group antigens in terms of biochemical structure and inheritance. 2. Describe the characteristics of Rh antibodies. 3. Translate the five major Rh antigens, genotypes, and haplotypes from Fisher-Race to Wiener nomenclature. 4. State the purpose of Fisher-Race, Wiener, Rosenfield, and ISBT nomenclatures. Background . How did this blood group get its name? . 1937 Mrs. Seno; Bellevue hospital . Unknown antibody, unrelated to ABO . Philip Levine tested her serum against 54 ABO-compatible blood samples: only 13 were compatible. Rhesus (Rh) blood group 1930s several cases of Hemolytic of the Fetus and Newborn (HDFN) published. Hemolytic transfusion reactions (HTR) were observed in ABO- compatible transfusions. In search of more blood groups, Landsteiner and Wiener immunized rabbits with the Rhesus macaque blood of the Rhesus monkeys. Rhesus (Rh) blood group 1940 Landsteiner and Wiener reported an antibody that reacted with about 85% of human red cell samples. It was supposed that anti-Rh was the specificity causing the “intragroup” incompatibilities observed. 1941 Levine found in over 90% of erythroblastosis fetalis cases, the mother was Rh-negative and the father was Rh-positive. Rhesus macaque Rhesus (Rh) blood group Human anti-Rh and animal anti- Rh are not the same. However, “Rh” was embedded into blood group antigen terminology. The
    [Show full text]
  • Complement Herbert L
    Host Defense 2011 Complement Herbert L. Mathews, Ph.D. COMPLEMENT Date: 4/11/11 Reading Assignment: Janeway’s Immunobiology, 7th Edition, pp. 54-55, 61-82, 406- 409, 514-515. Figures: (Unless otherwise noted) Janeway’s Immunobiology, 7th Edition, Murphy et al., Garland Publishing. KEY CONCEPTS AND LEARNING OBJECTIVES You will be able to describe the mechanism and consequences of the activation of the complement system. To attain the goals for these lectures you will be able to: a. List the components of the complement system. b. Describe the three activation pathways for complement. c. Explain the consequences of complement activation. d. Describe the consequence of complement deficiency. Page 1 Host Defense 2011 Complement Herbert L. Mathews, Ph.D. CONTENT SUMMARY Introduction Nomenclature Activation of Complement The classical pathway The mannan-binding lectin pathway The alternative pathway Biological Consequence of Complement Activation Cell lysis and viral neutralization Opsonization Clearance of Immune Complexes Inflammation Regulation of Complement Activation Human Complement Component Deficiencies Page 2 Host Defense 2011 Complement Herbert L. Mathews, Ph.D. Introduction The complement system is a group of more than 30 plasma and membrane proteins that play a critical role in host defense. When activated, complement components interact in a highly regulated fashion to generate products that: Recruit inflammatory cells (promoting inflammation). Opsonize microbial pathogens and immune complexes (facilitating antigen clearance). Kill microbial pathogens (via a lytic mechanism known as the membrane attack complex). Generate an inflammatory response. Complement activation takes place on antigenic surfaces. However, the activation of complement generates several soluble fragments that have important biologic activity.
    [Show full text]
  • Understanding the Immune System: How It Works
    Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
    [Show full text]
  • Activation of the Complement System on Human Endothelial Cells by Urban Particulate Matter Triggers Inflammation-Related Protein Production
    International Journal of Molecular Sciences Article Activation of the Complement System on Human Endothelial Cells by Urban Particulate Matter Triggers Inflammation-Related Protein Production Myoung Su Choi 1,† , Hyungtaek Jeon 2,†, Seung-Min Yoo 2 and Myung-Shin Lee 2,* 1 Department of Otorhinolaryngology, Eulji University Medical Center, Eulji University School of Medicine, Daejeon 35233, Korea; [email protected] 2 Department of Microbiology and Immunology, Eulji University School of Medicine, Daejeon 34824, Korea; [email protected] (H.J.); [email protected] (S.-M.Y.) * Correspondence: [email protected]; Tel.: +82-42-259-1662 † These authors have contributed equally to this work. Abstract: Exposure to particulate matter (PM) is becoming a major global health issue. The amount and time of exposure to PM are known to be closely associated with cardiovascular diseases. However, the mechanism through which PM affects the vascular system is still not clear. Endothelial cells line the interior surface of blood vessels and actively interact with plasma proteins, including the complement system. Unregulated complement activation caused by invaders, such as pollutants, may promote endothelial inflammation. In the present study, we sought to investigate whether urban PM (UPM) acts on the endothelial environment via the complement system. UPM-treated human endothelial cells with normal human serum showed the deposition of membrane attack complexes Citation: Choi, M.S.; Jeon, H.; Yoo, (MACs) on the cell surface via the alternative pathway of the complement system. Despite the forma- S.-M.; Lee, M.-S. Activation of the tion of MACs, cell death was not observed, and cell proliferation was increased in UPM-mediated Complement System on Human complement activation.
    [Show full text]
  • Targeted Exome Sequencing Defines Novel and Rare Variants in Complex Blood Group Serology Cases for a Red Blood Cell Reference Laboratory Setting
    IMMUNOHEMATOLOGY Targeted exome sequencing defines novel and rare variants in complex blood group serology cases for a red blood cell reference laboratory setting Elizna M. Schoeman ,1 Eileen V. Roulis ,1 Yew-Wah Liew,2 Jacqueline R. Martin,2 Tanya Powley,2 Brett Wilson,2 Glenda M. Millard ,1 Eunike C. McGowan ,1 Genghis H. Lopez ,1 Helen O’Brien ,1 Jennifer A. Condon,3 Robert L. Flower ,1 and Catherine A. Hyland 1 he key role of a modern red blood cell (RBC) ref- BACKGROUND: We previously demonstrated that erence laboratory in transfusion medicine is to targeted exome sequencing accurately defined blood employ serology to solve complex problems. group genotypes for reference panel samples Often, the lack of appropriate RBCs, sera, or characterized by serology and single-nucleotide T polymorphism (SNP) genotyping. Here we investigate reagents makes confident resolution of a complex case the application of this approach to resolve problematic difficult. Resources can be costly and scarce, if available at serology and SNP-typing cases. all, and often require collaboration and generosity of col- 1 STUDY DESIGN AND METHODS: The TruSight One leagues from other international laboratories. In addition, sequencing panel and MiSeq platform was used for reference laboratories commonly employ single- sequencing. CLC Genomics Workbench software was nucleotide polymorphism (SNP) typing microarrays for used for data analysis of the blood group genes RBC genotyping investigations; however, these arrays are implicated in the serology and SNP-typing problem. not comprehensive in their coverage of blood groups or 2-5 Sequence variants were compared to public databases variants. When the combination of traditional serologic listing blood group alleles.
    [Show full text]
  • Complement System: Immune Effector Mechanism Subhadipa 2020 What Is Complement System??? • Humoral Branch of the Immune System
    Subhadipa 2020 Complement system: Immune effector mechanism Subhadipa 2020 What is complement system??? • Humoral branch of the immune system. • Complement includes more than 30 soluble and cell-bound proteins. • After initial activation, the various complement components interact, in a highly regulated cascade, to carry out a number of basic functions including: Lysis of cells, bacteria, and viruses Opsonization, which promotes phagocytosis of particulate antigens Binding to specific complement receptors on cells of the immune system, triggering specific cell functions, inflammation, and secretion of immunoregulatory molecules. Immune clearance, which removes immune complexes from the circulation and deposits them in the spleen and liver Subhadipa 2020 Basic Functions The complement components Subhadipa 2020 • The proteins and glycoproteins that compose the complement system are synthesized mainly by liver hepatocytes, although significant amounts are also produced by blood monocytes, tissue macrophages, and epithelial cells of the gastrointestinal and genitourinary tracts. • These components constitute 5% (by weight) of the serum globulin fraction. Most circulate in the serum in functionally inactive forms as proenzymes, or zymogens, which are inactive until proteolytic cleavage, which removes an inhibitory fragment and exposes the active site. The complement-reaction sequence starts with an enzyme cascade. • Complement components are designated by numerals (C1–C9), by letter symbols (e.g., factor D), or by trivial names (e.g., homologous restriction factor). • Peptide fragments formed by activation of a component are denoted by small letters . In most cases, the smaller fragment resulting from cleavage of a component is designated “a” and the larger fragment designated “b” (e.g., C3a, C3b; note that C2 is an exception: C2a is the larger cleavage fragment).
    [Show full text]
  • Red Blood Cell Antigen Genotyping
    Red Blood Cell Antigen Genotyping Testing is useful in determining allelic variants predicting red blood cell (RBC) antigen phenotypes for patients with recent history of transfusion or with conflicting serological antibody results due to partial, variant, or weak expression antigens. Also Tests to Consider useful as an aid in management of hemolytic disease of the fetus and newborn (HDFN). Typical Testing Strategy Disease Overview Phenotype Testing Evaluates specific RBC antigen presence by serology Prevalence and/or Incidence Results can aid in selecting antigen negative RBC units Erythrocyte alloimmunization occurs in up to 58% of sickle cell patients, up to 35% in other transfusion-dependent patients, and in approximately 0.8% of all pregnant Antigen Testing, RBC Phenotype women. Extended 0013020 Method: Hemagglutination Serological testing includes K, Fya, Fyb, Jka, Symptoms Jkb, S, s (k, cellano, testing performed if indicated) to assess maternal or paternal RBC Transfusion reactions or HDFN can occur due to alloimmunization: phenotype status. Antigen Testing, Rh Phenotype 0013019 Intravascular hemolysis: hemoglobinuria, jaundice, shock Extravascular hemolysis: fever and chills Method: Hemagglutination HDFN: fetal hemolytic anemia, hepatosplenomegaly, jaundice, erythroblastosis, Antigen testing for D, C, E, c, and e to assess neurological damage, hydrops fetalis maternal, paternal, or newborn Rh phenotype status Clinical presentation is variable and dependent upon the specific antibody and recipient factors Genotype Testing May help
    [Show full text]
  • Anti-Rhd Immunoglobulin in the Treatment of Immune Thrombocytopenia
    REVIEW Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia Eric Cheung Abstract: Immune thrombocytopenia (ITP) is an acquired bleeding autoimmune disorder Howard A Liebman characterized by a markedly decreased blood platelet count. The disorder is variable, frequently having an acute onset of limited duration in children and a more chronic course in adults. Jane Anne Nohl Division of Hematology A number of therapeutic agents have demonstrated effi cacy in increasing the platelet counts in and Center for the Study of Blood both children and adults. Anti-RhD immunoglobulin (anti-D) is one such agent, and has been Diseases, University of Southern California-Keck School of Medicine, successfully used in the setting of both acute and chronic immune thrombocytopenia. In this Los Angeles, CA, USA report we review the use of anti-D in the management of ITP. While the FDA-approved dose of 50 mg/kg has documented effi cacy in increasing platelet counts in approximately 80% of children and 70% of adults, a higher dose of 75 μg/kg has been shown to result in a more rapid increase in platelet count without a greater reduction in hemoglobin. Anti-D is generally inef- fective in patients who have failed splenectomy. Anti-RhD therapy has been shown capable of delaying splenectomy in adult patients, but does not signifi cantly increase the total number of patients in whom the procedure can be avoided. Anti-D therapy appears to inhibit macrophage phagocytosis by a combination of both FcR blockade and infl ammatory cytokine inhibition of For personal use only. platelet phagocytosis within the spleen.
    [Show full text]